Birdwatch Note
2025-02-05 21:09:35 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
O SUS faz o tratamento de Distrofia Muscular de Duchenne com o Elevidys dentro da idade indicada pelo laboratório, com o paciente tendo até 7 anos e 11 messes. Acima dessa idade não há tratamento comprovado e o SUS não cobre tratamentos experimentais. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/anvisa-aprova-registro-de-primeiro-produto-de-terapia-genica-para-distrofia-muscular-de-duchenne-dmd https://www.mda.org/press-releases/mda-celebrates-fda-approval-of-sarepta-therapeutics-elevidys-for-treatment-of-duchenne-muscular-dystrophy https://noticias.stf.jus.br/postsnoticias/esclarecimento-sobre-decisoes-envolvendo-concessao-do-medicamento-elevidys/
Written by DEF50FD4AFA8C4359F1EACC11322B5F6DB799EF77211DA337BF5C3753C9D571F
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1886927633427976311
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1887247222729052348
- noteId - 1887247222729052348
- participantId -
- noteAuthorParticipantId - DEF50FD4AFA8C4359F1EACC11322B5F6DB799EF77211DA337BF5C3753C9D571F Participant Details
- createdAtMillis - 1738789775913
- tweetId - 1886927633427976311
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- O SUS faz o tratamento de Distrofia Muscular de Duchenne com o Elevidys dentro da idade indicada pelo laboratório, com o paciente tendo até 7 anos e 11 messes. Acima dessa idade não há tratamento comprovado e o SUS não cobre tratamentos experimentais. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/anvisa-aprova-registro-de-primeiro-produto-de-terapia-genica-para-distrofia-muscular-de-duchenne-dmd https://www.mda.org/press-releases/mda-celebrates-fda-approval-of-sarepta-therapeutics-elevidys-for-treatment-of-duchenne-muscular-dystrophy https://noticias.stf.jus.br/postsnoticias/esclarecimento-sobre-decisoes-envolvendo-concessao-do-medicamento-elevidys/
Note Ratings
| rated at | rated by | |
| 2025-02-06 18:35:31 -0600 | Rating Details | |
| 2025-02-06 18:05:53 -0600 | Rating Details | |
| 2025-02-06 17:50:12 -0600 | Rating Details | |
| 2025-02-06 17:28:59 -0600 | Rating Details | |
| 2025-02-06 12:46:02 -0600 | Rating Details | |
| 2025-02-06 12:27:31 -0600 | Rating Details | |
| 2025-02-06 06:42:55 -0600 | Rating Details | |
| 2025-02-06 04:07:06 -0600 | Rating Details | |
| 2025-02-06 03:44:34 -0600 | Rating Details | |
| 2025-02-05 20:48:04 -0600 | Rating Details | |
| 2025-02-05 19:36:45 -0600 | Rating Details | |
| 2025-02-05 18:07:35 -0600 | Rating Details | |
| 2025-02-05 15:36:22 -0600 | Rating Details | |
| 2025-02-05 15:30:12 -0600 | Rating Details | |
| 2025-02-07 05:24:12 -0600 | Rating Details | |
| 2025-02-06 19:33:03 -0600 | Rating Details | |
| 2025-02-07 04:18:24 -0600 | Rating Details | |
| 2025-02-07 02:46:13 -0600 | Rating Details | |
| 2025-02-06 21:12:05 -0600 | Rating Details | |
| 2025-02-06 20:54:03 -0600 | Rating Details | |
| 2025-02-06 20:50:14 -0600 | Rating Details | |
| 2025-02-06 20:35:28 -0600 | Rating Details | |
| 2025-02-06 19:26:22 -0600 | Rating Details | |
| 2025-02-06 19:16:55 -0600 | Rating Details | |
| 2025-02-06 18:36:22 -0600 | Rating Details | |
| 2025-02-06 18:18:27 -0600 | Rating Details | |
| 2025-02-06 17:40:25 -0600 | Rating Details | |
| 2025-02-06 15:21:30 -0600 | Rating Details | |
| 2025-02-06 15:03:54 -0600 | Rating Details | |
| 2025-02-06 14:26:27 -0600 | Rating Details | |
| 2025-02-06 14:16:04 -0600 | Rating Details | |
| 2025-02-06 14:10:15 -0600 | Rating Details | |
| 2025-02-06 13:53:50 -0600 | Rating Details | |
| 2025-02-06 12:47:58 -0600 | Rating Details | |
| 2025-02-06 12:35:16 -0600 | Rating Details | |
| 2025-02-06 05:28:54 -0600 | Rating Details | |
| 2025-02-05 23:22:11 -0600 | Rating Details | |
| 2025-02-05 21:27:57 -0600 | Rating Details | |
| 2025-02-05 17:40:09 -0600 | Rating Details | |
| 2025-02-05 15:54:31 -0600 | Rating Details | |
| 2025-02-06 22:48:23 -0600 | Rating Details | |
| 2025-02-06 20:54:52 -0600 | Rating Details | |
| 2025-02-06 19:34:10 -0600 | Rating Details | |
| 2025-02-06 14:23:56 -0600 | Rating Details | |
| 2025-02-06 13:42:47 -0600 | Rating Details | |
| 2025-02-06 13:32:44 -0600 | Rating Details | |
| 2025-02-05 19:34:13 -0600 | Rating Details | |
| 2025-02-05 16:15:38 -0600 | Rating Details | |
| 2025-02-15 06:15:57 -0600 | Rating Details |